BYSL (bystin-like) is a conserved eukaryotic protein with dual roles in ribosomal biogenesis and cancer progression. Functionally, BYSL is essential for 40S ribosomal subunit biogenesis through processing of 20S pre-rRNA precursor and 18S RNA 1, and may regulate trophinin-dependent cell adhesion during embryo implantation 1. Mechanistically, BYSL operates through multiple signaling pathways: it promotes glioblastoma migration and epithelial-mesenchymal transition via GSK-3β/β-catenin signaling 2, enhances glioma growth through mTORC2/AKT pathway activation via interaction with RIOK2 3, and forms a complex with DDX49 in thyroid cancer that impairs tumor-suppressive miR-145-5p biogenesis 4. In osteosarcoma, BYSL promotes invasion and EMT under hypoxia through Nrf2 upregulation, opposed by miR-378a-3p regulation 5. Clinical significance is substantial: elevated BYSL expression correlates with poor prognosis and serves as a prognostic biomarker across multiple cancers including chondrosarcoma 6, melanoma 7, glioblastoma 2, and colorectal cancer 8. BYSL represents a potential therapeutic target across multiple malignancies.